RFC
SRPT icon

Russell Frank Company’s Sarepta Therapeutics SRPT Stock Holding History

Russell Frank Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-279
Closed -$6K – 3026
2014
Q3 		$6K Buy
+279
New +$6.3K ﹤0.01% 2828
2013
Q4 		– Sell
-4,653
Closed -$220K – 3030
2013
Q3 		$220K Buy
4,653
+170
+4% +$6.55K ﹤0.01% 2737
2013
Q2 		$171K Buy
+4,483
New +$160K ﹤0.01% 2614

Other funds holding SRPT

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Russell Frank Company's SRPT Position: Q4 2014 in Review

Russell Frank Company sold out of Sarepta Therapeutics (SRPT) in Q4 2014, closing a stake of 279 shares — an estimated $6K sold.

Russell Frank Company first reported a position in SRPT in Q2 2013 and held it in 3 quarters. The position peaked at $220K in Q3 2013. 120 funds tracked by Wall St. Rank hold SRPT as of Q4 2014.

  • Russell Frank Company reported no remaining Sarepta Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Russell Frank Company sold 279 Sarepta Therapeutics shares in Q4 2014, an estimated $6K.
  • Russell Frank Company first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 3 quarters.
  • Russell Frank Company's Sarepta Therapeutics position peaked at $220K in Q3 2013.
  • 120 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2014.

Based on Russell Frank Company's 13F filing for Q4 2014, filed 5 Feb 2015.